GlassScriptPhysician profile
Kitty Carter-Wicker
NPI 1043210974
$1,424.74
in general payments reported to CMS, 2019-2025
14 companies · $789 in 2025
The $789 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $55.85 · 2022: $48.43 · 2023: $108 · 2024: $314 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $331.86 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $209.33 | 2025 | Benlysta, Shingrix, Arexvy |
| Viiv Healthcare Company | $147.67 | 2024-2025 | Apretude |
| Novo Nordisk INC | $139.23 | 2021-2025 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $114.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.85 | 2019 | |
| Pfizer INC. | $92.94 | 2023 | |
| Gilead Sciences, INC. | $85.95 | 2024-2025 | |
| Celgene Corporation | $48.43 | 2022 | |
| Seqirus USA INC | $44.74 | 2025 | Flucelvax, Fluad |
| Argenx US, INC. | $31.15 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Abbott Laboratories | $30.62 | 2025 | Infinity |
| Sanofi Pasteur INC. | $23.22 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.12 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitty Carter-Wicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.